Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Ropivacaine

USE IF: Epidural (labor/post-op), nerve blocks, infiltration

AVOID IF: No lipid rescue available, IV use, Bier block

Ropivacaine

Amide local anesthetic (long-acting, S-enantiomer)

Regional anesthesiaEpiduralNerve blockSafer than bupivacaineLAST risk

Indication

Epidural (labor/post-op), nerve blocks, infiltration

At a glance

INDICATION -> Safer long-acting alternative to bupivacaine for regional anesthesia

ADULT DOSE -> Peripheral block up to 300 mg; epidural infusion 12-28 mg/hr

MAX DOSE -> Single block 300 mg; epidural 24h total 770 mg

CONTRA -> No lipid rescue available, IV use, Bier block

ANTIDOTE -> Lipid Emulsion 20%

Quick facts

Onset

10-20 min (epidural), 10-25 min (block)

Duration

Peak 30-45 min; duration 3-14 h (dose-dependent); half-life ~1.8 h IV, ~4 h epidural.

Routes

Epidural, nerve block, infiltration (NOT for IV administration; systemic IV use contraindicated)

Pregnancy

Safe (labor epidural)

Renal

No adjustment for short-term use

Hepatic

Reduce dose

Do not miss

Time to action: onset usually 10-25 min depending on route

Critical timing risk

  • LAST can be delayed (hours into infusion).

Critical actions

  • CYP1A2 inhibitors (e.g., fluvoxamine) can significantly increase levels and toxicity.
  • Always inject incrementally with aspiration.
  • Lipid emulsion MUST be immediately available.

Antidote

  • Lipid emulsion 20%: 1.5 mL/kg bolus -> infusion 0.25 mL/kg/min (repeat bolus if needed).

High-risk scenarios

  • Do NOT confuse ropivacaine dosing with bupivacaine.

Key interactions

  • Fluvoxamine.
  • Ciprofloxacin.
  • Other local anesthetics.
  • Amiodarone.
  • Methemoglobinemia-inducing drugs.

Indications

Primary

  • Labor epidural analgesia
  • Surgical epidural anesthesia
  • Peripheral nerve blocks

Secondary

  • Postoperative epidural infusion
  • Rib fracture analgesia

Other

  • TAP block (off-label)
  • Paravertebral block (off-label)
  • Wound infiltration

Dosing

Standard: Epidural 0.2% infusion 6-14 mL/hr

Max daily dose

  • Single peripheral block: up to 300 mg.
  • Epidural 24-hour total: up to 770 mg.

Adult - Epidural

  • Adult epidural surgical dose: 75-200 mg.
  • Epidural infusion: 12-28 mg/hr (e.g., 0.2% at 6-14 mL/hr).

Peripheral block

  • Peripheral block: 0.5-0.75%, up to 300 mg.

Pediatric

  • Caudal: 2 mg/kg.
  • Infusion: 0.2-0.4 mg/kg/hr.

Renal adjustment

  • Monitor and consider reduction with prolonged infusion.

Hepatic adjustment

  • Reduce dose by ~25-50% in impairment.

Warnings

Clinical warnings

  • LAST risk remains and may be delayed.
  • CNS toxicity can progress to seizures.
  • Cardiac toxicity is lower than bupivacaine but still can be fatal.
  • Avoid combining with other local anesthetics -> additive systemic toxicity.
  • Hypotension can occur with epidural use.
  • High spinal can cause respiratory arrest.
  • Methemoglobinemia is rare but possible.
  • Intra-articular use has chondrolysis risk.

Adverse effects

  • Common: hypotension, nausea, dizziness, sensory/motor block changes.
  • Serious: seizures, arrhythmia, cardiovascular collapse, LAST.

Contraindications / caution

Do not use

  • IV administration.
  • Bier block.
  • Hypersensitivity to amide local anesthetics.

Use caution / avoid high doses

  • Hepatic impairment.
  • Elderly.
  • Cardiac disease.
  • CYP1A2 inhibitors.
  • Neonates.

Drug interactions

  • Fluvoxamine -> major reduction in clearance (~70%) and higher LAST risk.
  • Erythromycin + fluvoxamine can markedly increase exposure.
  • Ciprofloxacin -> increased levels via CYP1A2 inhibition.
  • Other local anesthetics -> additive systemic toxicity.
  • Amiodarone -> increased cardiac risk.
  • Methemoglobinemia-inducing drugs -> additive risk.

Special populations

Pediatrics

Caudal and infusion dosing require strict weight-based specialist protocols.

Pregnancy

Preferred option for labor epidural analgesia.

Breastfeeding

Generally safe; minimal transfer.

Elderly

Reduce dose by ~20-30%.

Liver disease

Reduce dose significantly.

Renal impairment

Usually no adjustment for short-term use; monitor if prolonged infusion.

Administration

  • Epidural: incremental 3-5 mL dosing; test dose required.
  • Epidural infusion should run via pump only.
  • Nerve block: ultrasound guidance preferred.
  • Always aspirate before injection to reduce intravascular risk.
  • Reduce infusion rate after 24 hours where appropriate.
  • Lipid emulsion must be immediately available.

Monitoring

  • CNS symptoms for early LAST detection.
  • ECG for arrhythmia monitoring.
  • Blood pressure for hypotension.
  • Block level (sensory and motor).
  • Respiratory status.
  • Cumulative dose tracking.
  • Confirm lipid emulsion availability.

Overdose / toxicity

STOP infusion immediately -> airway + 100% oxygen -> treat as LAST.

Recognition

  • Toxic CNS levels may occur around >4-6 mg/L.
  • Tingling/tinnitus can progress to seizures and cardiovascular collapse.

Immediate actions

  • Airway support + 100% oxygen.
  • Benzodiazepines for seizures.
  • Lipid emulsion 20% bolus 1.5 mL/kg, then infusion 0.25 mL/kg/min.

Antidote

  • Lipid Emulsion 20% LAST protocol.

Decontamination

  • Not typically applicable for parenteral local anesthetic toxicity.

Escalation

  • ICU with prolonged monitoring for delayed recurrence/toxicity progression.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

Relative safety

  • Less cardiotoxic than bupivacaine due to reduced cardiac sodium channel affinity.
  • Safer than bupivacaine does not mean safe; LAST remains a major risk.

Labor epidural fit

  • Often preferred for labor epidural because motor block is typically less pronounced.

Delayed LAST

  • Delayed LAST may occur hours into infusion -> sudden CNS or cardiovascular collapse.

Fluvoxamine alert

  • Fluvoxamine interaction is high-risk and often under-recognized.

Infusion strategy

  • Reduce infusion rate after ~24 hours when clinically feasible.
  • Continuous infusion increases risk of accumulation -> monitor closely for delayed LAST.

Dose governance

  • Always track cumulative dose carefully.

Rescue readiness

  • Lipid rescue must be physically present before starting regional infusion.

Pharmacokinetics

  • Highly protein bound (~94%).
  • Hepatic metabolism with CYP1A2 as a major pathway.
  • Renal excretion of metabolites.
  • Clearance is reduced by CYP1A2 inhibitors.
  • Can accumulate with prolonged infusion.

Mechanism of action

  • Blocks voltage-gated sodium channels.
  • Preferentially produces sensory block over motor block at typical concentrations.
  • S-enantiomer profile contributes to lower cardiotoxicity relative to bupivacaine.
  • Use-dependent channel blockade.

Common brand names

Saudi Arabia

Naropin

Global

Ropivacaine Fresenius Kabi · Generic ropivacaine

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Widely available across GCC hospitals as Naropin.
  • Preferred over bupivacaine for labor epidural due to less motor block.
  • Used in ER/ICU pathways for rib fractures (thoracic epidural/paravertebral).
  • Generic ropivacaine is widely available in UAE and Saudi hospitals.

Saudi Arabia — confirm with local formulary.